Stereotaxis (STXS) investor relations material

Company overview and business model

• Designs, manufactures, and markets robotic systems and instruments for interventional labs, focusing on Robotic Magnetic Navigation for endovascular interventions, especially cardiac ablation procedures for arrhythmias.

• Expanding clinical focus to coronary, neuro, and peripheral interventions, supported by substantial clinical evidence and global adoption in over 150,000 procedures.

• Offers bundled solutions with strategic partners, including x-ray systems and digital imaging, with recurring revenue from disposables, service, and software updates.

• Recent acquisition of Robocath, a French innovator in robotic technology for interventional cardiology and neurointerventions, for $20 million in cash and stock, plus potential $25 million earnout.

Financial performance and metrics

• Robocath acquisition is not expected to be accretive in the near term and will increase operating losses; Robocath has a history of operating losses and negative cash flows.

• Extended $1.1 million in operating loans to Robocath prior to acquisition closing, repaid at closing.

Use of proceeds and capital allocation

• No proceeds will be received from the resale of shares by selling stockholders; prior proceeds from warrant exercises were used for general corporate purposes.

• Earnout payments for Robocath acquisition may be made in cash, stock, or warrants, subject to a 19.9% cap of pre-acquisition outstanding shares.